Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

9480	Companies
185559	Keywords
117951	Articles
99390	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 04/25/2025 at 18:00, 7 months 10 days ago

Postponement of the publication of the annual financial statements
Biophytis announces postponement of annual financial statements publication due to refinancing operation. Company aims to release by end of May 2025

Financial Statements Biophytis 2024 Postponement Refinancing Operation
REGULATED PRESS RELEASE

published on 04/25/2025 at 18:00, 7 months 10 days ago

Report de la publication des comptes annuels
Biophytis SA annonce le report de la publication de ses comptes annuels, clos le 31 décembre 2024, en raison d'un refinancement de 2,6 millions d'euros. La Société met tout en œuvre pour finaliser et publier ses états financiers avant fin mai 2025

États Financiers Comptes Annuels Report Refinancement Biophytis SA
BRIEF

published on 04/22/2025 at 07:05, 7 months 13 days ago

Biophytis et son avancée dans le traitement de l'obésité

Biophytis Marché Mondial Obésité GLP-1 Masse Musculaire
BRIEF

published on 04/22/2025 at 07:05, 7 months 13 days ago

Biophytis Aims for Enhanced Mobility in Obesity Treatment

Biophytis Obesity Treatment Muscle Preservation GLP-1 Therapies Biotechnology Market
REGULATED PRESS RELEASE

published on 04/22/2025 at 07:00, 7 months 13 days ago

Biophytis cible la restauration de la mobilité chez les patients obèses
Biophytis développe des traitements pour restaurer la mobilité des patients obèses. Leur candidat-médicament BIO101, combiné avec GLP-1, améliore la force musculaire. Vers une nouvelle génération de thérapies axées sur la qualité de la perte de poids

Biophytis Mobilite BIO101 Obésité GLP-1
REGULATED PRESS RELEASE

published on 04/22/2025 at 07:00, 7 months 13 days ago

Biophytis targets mobility restoration in patients with obesity
Biophytis strengthens position in developing treatments for age-related muscle function loss in obesity care by focusing on quality weight loss and mobility restoration with BIO101 and GLP-1 therapies

Biophytis Muscle Function Obesity Care Quality Weight Loss Mobility Restoration
PRESS RELEASE

published on 04/22/2025 at 06:59, 7 months 13 days ago

Biophytis targets mobility restoration in patients with obesity
Biophytis focuses on preserving muscle function in obesity patients treated with GLP-1 therapies by developing BIO101. The aim is to improve quality of weight loss and mobility

Biophytis BIO101 Obesity Muscle Function GLP-1 Therapies
BRIEF

published on 04/09/2025 at 07:05, 7 months 26 days ago

Biophytis lance la phase 2 de l'essai clinique OBA pour l'obésité

Investissement Biophytis Essai Clinique BIO101 Obésité
BRIEF

published on 04/09/2025 at 07:05, 7 months 26 days ago

Biophytis Initiates Phase 2 OBA Clinical Trial for Obesity Treatment

Biophytis Obesity Treatment Clinical Trial BIO101 Partnership Goal
REGULATED PRESS RELEASE

published on 04/09/2025 at 07:00, 7 months 26 days ago

Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
Biophytis confirms the Phase 2 OBA Clinical Trial launch in obesity, continuing development of BIO101 to reduce muscle strength loss. Seeking pharmaceutical partner for co-development

Biophytis BIO101 Obesity Pharmaceutical Partner Phase 2 OBA Clinical Trial

Accesswire

Published on 12/05/2025 at 21:45, 42 minutes ago

When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 57 minutes ago

The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once
Published on 12/05/2025 at 21:20, 1 hour 7 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published on 12/05/2025 at 21:00, 1 hour 27 minutes ago

The Repricing Event: Why Multiple Global Industries Are Suddenly Moving Toward SMX
Published on 12/05/2025 at 20:25, 2 hours 2 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 22:15, 11 minutes ago

CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 15 minutes ago

EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 3 hours 29 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 4 hours ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 4 hours 11 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd

Les Echos

Published on 12/05/2025 at 17:18, 5 hours 9 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 5 hours 9 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 7 hours 16 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 7 hours 16 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 8 hours 28 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE